According to a report by the Associated Press the Food and Drug Administration said it has received reports of liver damage in patients taking Multaq (dronedarone) tablets, including two cases in which patients had to have their livers removed.
Multaq, approved by the FDA in July 2009, is marketed by Sanofi-Aventis SA. The drug is used to treat atrial flutter and atrail fibrillation, which are irregular heart rhythms that can result in stroke. Multaq carries a black box warning stating that it can cause severe adverse reactions and death in people with recent severe heart failure.